Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules - ResearchAndMarkets.com

The "Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules" newsletter has been added to ResearchAndMarkets.com's offering.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Wednesday, June 26, 2019
Information
Tags: 
Health, Pharmaceutical, Psychoactive drugs, Antidiarrhoeals, Euphoriants, Mitragyna speciosa, Naucleeae, Opioids, Health, Food and Drug Administration, FDA warning letter
⚠generated by AI ↴
Summary
Key Points: 
  • The "Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules" newsletter has been added to ResearchAndMarkets.com's offering.
  • The kratom industry is facing continued scrutiny as a contract manufacturer recently received a warning letter from the US FDA, coincidentally made public on the same day the published standards for safety from the American Kratom Association were released.
  • While the FDA warning letter to Avalon Packaging, Inc., a contract manufacturer of kratom, cited issues with manufacturing, including salmonella contamination, the agency refrained referencing its 2017 findings that found kratom constituent ingredients to be opioids and potentially in need of being scheduled as controlled substances by the DEA.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20190626005680/en/


The "Kratom Industry Offers Own Standards As Another Firm Warned About FDA Rules" newsletter has been added to ResearchAndMarkets.com's offering.

The kratom industry is facing continued scrutiny as a contract manufacturer recently received a warning letter from the US FDA, coincidentally made public on the same day the published standards for safety from the American Kratom Association were released.

While the FDA warning letter to Avalon Packaging, Inc., a contract manufacturer of kratom, cited issues with manufacturing, including salmonella contamination, the agency refrained referencing its 2017 findings that found kratom constituent ingredients to be opioids and potentially in need of being scheduled as controlled substances by the DEA.

For more information about this newsletter visit https://www.researchandmarkets.com/r/3jfeah

Copyright: 
Copyright Business Wire 2019